Crystal Adam 4
4 · Tango Therapeutics, Inc. · Filed Nov 2, 2023
Insider Transaction Report
Form 4
Crystal Adam
President, R&D
Transactions
- Sale
Common Stock
2023-11-01$8.39/sh−7,507$62,994→ 81,250 total
Footnotes (1)
- [F1]Includes 7,507 shares that were acquired on October 31, 2023 pursuant to the Tango Therapeutics, Inc. 2021 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c).